EGFR and head and neck cancer: Some studies support the use of cetuximab, which mediated antibody-dependent cytotoxicity (ADCC) against epidermal growth factor receptor- (EGFR-) overexpressing tumor cells, and PD-1 blockade can reverse NK cell dysfunction in head and neck cancer [66].